



REPUBLIC OF ZAMBIA
MINISTRY OF HEALTH

ZAMBIA ESSENTIAL MEDICINES LIST

06
2025



REPUBLIC OF ZAMBIA
MINISTRY OF HEALTH

ZAMBIA ESSENTIAL MEDICINES LIST (ZEML)

Users of this publication are encouraged to send any comments and queries to the following address:

THE PERMANENT SECRETARY

MINISTRY OF HEALTH

NDEKE HOUSE

P.O Box 30205

LUSAKA-ZAMBIA

Email: ps@moh.gov.zm

Proposals for amendments to the list should be sent to the same address using the ZEML Amendment Form (Refer to Appendix)

CONTENTS

Changes made to 6th Version of the Zambia Essential Medicines List	vi
Acknowledgements	x
Zambia National Formulary Committee 2024 - 2027	xi
Introduction	1
Zambia Essential Medicines List	2
1. Medicines used in anaesthesia	2
2. Medicines acting on the gastrointestinal system	2
3. Medicines acting on the central nervous system	3
4. Medicines used in the treatment of infections	6
5. Medicines used in the treatment of endocrine system disorders, obstetrics, gynaecology, and contraception	11
6. Medicines used in the treatment of diseases of the respiratory system and allergy	14
7. Medicines used in the treatment of cardiovascular system disorders	15
8. Medicines used in the treatment of malignant disease: anti-neoplastic medicines	17
9. Medicines acting on the eye	18
10. Blood and Blood products	20
11. Nutrition	20
12. Medicines acting on the skin	21
13. Medicines used in the treatment of diseases of the ear, nose and throat	23
14. Medicines used in the treatment of musculoskeletal disorders	23
15. Immunological products	24
16. Antidotes and other substances used in poisoning	25
Appendices	26

CHANGES MADE TO 6TH VERSION OF THE ZAMBIA ESSENTIAL MEDICINES LIST

In this 6th version of the ZEML document, changes have been made from its previous version to improve the delivery of information and for the purpose of ensuring that this document is updated based on current treatment guidelines of the conditions the medicines are being used for. These are some of the changes and improvements made to this document:

- In this version, antibiotics/antibacterials have been categorized using the WHO AWaRe classification of Antibiotics to emphasize the significance of their appropriate use. The classification is a tool for antibiotic stewardship at local, national and global levels with the aim of reducing antimicrobial resistance. The categories are as follows:
 - A – Access
 - Wa – Watch
 - Re – Reserve
- Where applicable, levels of health care where certain medicines were previously found have been lowered to improve access and service delivery to the lowest levels. Levels in this document are as follows:
 - I – Health Posts
 - II – First level Hospitals
 - III – General Hospitals
 - IV – Tertiary and Specialized Hospitals
- All medicines have been reviewed in terms of their Vital, Essential and Non-essential (VEN) classification and where applicable, some medicines' classifications were updated based on current condition patterns and treatment guidelines.
- Some medicines were proposed for deletion based on current treatment guidelines and better options to ensure effective management of the public. Deleted medicines from the previous version include:

Deletions

Anaesthesia
Halothane

Medicines used in the treatment of Infections (anti-tuberculosis)
Streptomycin

Blood and Blood Products (Anti-haemorrhagic)
Aminocaproic acid

- Treatment guidelines for a lot of conditions are updated frequently based on current disease patterns, effective and safe treatment options and availability of medicines for enhanced health care delivery to the Zambian population. It is for this fact that the following medicines have been added to this version of the ZEML.

Additions

General Anaesthesia	Local Anaesthetics
Nitrous oxide	Lignocaine
Muscle relaxant	Antispasmodics
1. Suxamethonium	Hyoscine butyl bromide
2. Atracurium	
3. Cisatracurium	
4. Rocuronium	

Medicines acting on the Central Nervous System	
Anxiolytics	Selective serotonin reuptake inhibitors
1. Clonazepam	1. Escitalopram
2. Midazolam	2. Mirtazapine
3. Chlordiazepoxide	Medicines used in Parkinsonism and related disorders
Antipsychotics	Procyclidine
1. Chlorpromazine	Medicines used for Nausea and Vomiting

2. Haloperidol	Prochlorperazine
1. Fluphenazine	Analgesics
2. Risperidone	Non-opioids analgesics
3. Risperidone	Paracetamol (Acetaminophen)
1. Quetiapine	
2. Olanzapine	
3. Clozapine	
4. Disulfiram	

Medicines used in the treatment of Infections	
Antibacterial medicines	Anti-protozoal medicines
1. Piperacillin/Tazobactam	Antimalarials
2. Meropenem	1. Primaquine
3. Vancomycin	2. Pyrimethamine
Aminoglycosides	3. Dapsone
Amikacin	Antivirals (Covid-19)
Quinolones	1. Nirmatrelvir/ Ritonavir
Nalidixic acid	2. Remdesivir
Lincosamides	Antiretroviral Medicines used in HIV infection
Clindamycin	Cabotegravir
Cephalosporins and Cephamycins	
1. Cefixime	
2. Cefpodoxime	

Medicines used in the treatment of Endocrine system disorders, Obstetrics, Gynaecology, and Contraception

Medicines used in Diabetes mellitus	Oestrogens and progestogens
1. Long-acting Insulin (Glargine, Determir)	1. Micronized Progestogen
2. Semaglutide	2. Levonogestrol
Oral Antihyperglycaemics	3. Hormonal IUCD
1. Glimepiride + Metformin	Other endocrine medicines
2. Sitagliptin	Letrazole

3. Vildagliptin	Corticosteroids
4. Dapagliflozin	Betamethasone
5. Pioglitazone	
Other medicines administered to the pregnant woman	
Etamsylate	

Medicines used in the treatment of respiratory system disorders and allergy (Antihistamines)
Chlorphenamine

Apnea of Prematurity	
1. Caffeine Citrate	2. Potassium-sparing diuretics
3. Surfactant (Beractant)	4. Eplerenone

Medicines used in the treatment of cardiovascular system disorders (Angiotensin II receptor blockers)
Sacubitril + Valsartan

Medicines used in the treatment of malignant diseases: Anti-neoplastic medicines	
1. Irinotecan	2. Liposomal Doxorubin

Blood and Blood Products (Anti-coagulants)	
Rivaroxaban	Dabigatran

Oral antifungals	
1. Griseofulvin	2. Terbinafine
Keratoplastics and keratolytics	
Silver Nitrate Pencil	

Acknowledgement

The Zambia National Formulary Committee is grateful to the Ministry of Health (MoH) for its support during the preparation of this edition of the Formulary. The Committee would also like to thank Clinton Health Access Initiative (CHAI), World Health Organization (WHO), United Nations Population Fund (UNFPA), and PATH with support from Flemming Fund for financial and technical support towards the preparation of the Formulary. The Committee further acknowledges the technical advice and contributions received from various health professionals across various institutions in the country. Special thanks go to PATH for the support rendered in editing, proof-reading and typesetting of this document.

The Committee would also like to thank the following Pharmacists from ZNFC Secretariat for their support in facilitating the review of this document: Mr. Maxwell Kasonde (MoH), Mr. Kandandu Chibosha (MoH), Mrs. Thikondane Mphande-Muyunda (UTH-WNH), and Mr. Pious Haachizo (UTH-CDH).



Dr. Lisulo Walubita

Director - Clinical Care & Diagnostics Services
Ministry of Health

ZAMBIA NATIONAL FORMULARY COMMITTEE 2024- 2027

1. Dr Justo BANDA
Renal Specialist/SMS, NTH (Chairperson)
2. Prof Lloyd MATOWE
Dean, School of Pharmacy, Manica University
(Vice-Chairperson)
3. Dr Kor CHIYENU Consultant Physician/SMS
LUTH
4. Prof Lloyd MULENGA
Director Infectious Diseases
MoH
5. Dr Malan MALUMANI
Consultant Dermatologist
LUTH/MU
6. Mr Matthews MWALE
Chief Pharmacist
UTH-CDH
7. Dr Jane Mwamba MUMBA
Consultant-Obstetrician/Gynecologist
NTH
8. Mrs Rachel Msimuko MUYOMA
Senior Manager – Supply Planning
ZAMMSA
9. Dr Matimba DINDI
Consultant-Paediatrician
UTH-CH
10. Mr Samuel MUYUNDA
Pharmacist-Head of Pharmacy
UTH-CH
11. Dr Christopher CHANDA
Consultant Anaesthesia
UTH-AH
12. Mr. Friday SAKALA
Pharmacist
Chainama Hills Hospitals
13. Mr. Abraham MUKESALA
Chief Pharmacist, Lusaka PHO
14. Mr. Enock CHIKATULA
Chief Pharmacist
LMUTH
15. Dr Henry MULENGA
Head Physician
Lusaka Trust Hosp
16. Dr Susan Citonge MSADABWE
Consultant/SMS, UTH-CDH
17. Dr Francisca BWALYA
Consultant Psychiatrist
MoH
18. Mr Divine MBAMBALA
Clinical Pharmacist Internal Medicine
UTH-AH
19. Dr Mwamba KATEMA
Public Health Specialist
Mahatma Ghandi Clinic
20. Dr Joseph Yowela CHIZIMU
AMR National Focal Point and Coordinator
ZNPHI
21. Dr Chileshe LUKWESA
Clinical Microbiologist
Lusaka DHO
22. Mrs Anita Bhebhe MOYO
Pharmacist/Epidemiologist
UTH-AH/PSZ
23. Mr Martin KAMPAMBA
Lecturer, School of Health Sciences, UNZA
24. Mrs Constance Sakala CHISHA
Senior Registration Officer-Human Medicine,
ZAMRA

SECRETARIAT

1. Mr Maxwell KASONDE
Assistant Director-Pharmaceutical Services, MoH
2. Mr Kandandu CHIBOSHA
Chief Pharmacist-RDU
MoH
3. Mrs Thikondane MPHANDE-MUYUNDA
Pharmacist UTH-WNH
4. Mr Pious HAACHIZO
Senior Pharmacist
UTH-CDH

TECHNICAL REVIEWERS

1. Dr Stephen BWALYA
National Malaria Elimination Center
2. Dr Mwiya MWIYA
UTH-HIV Program
3. Dr Maureen CHISEMBELE
UTH-WNH
4. Dr Justin MULINDWA
UTH-CDH
5. Dr Sylvia MACHONA
UTH-WNH
6. Dr Christopher KAPESHI
MoH
7. Dr Thandiwe Tembo
Chainama Hills Hospital
8. Dr Tebuho MATEELE
LMUTH
9. Mr Boyd MWANASHIMBALA
LUTH
10. Mr Justin MUSUMALI
UTH-WNH

11. Mr Benjamin SOLOCHI
PATH
12. Mr Peter LISULO
WHO
13. Dr Chanda CHITALU
UTH-Adult
14. Dr Joseph PHIRI
NHH
15. Ms Namuchindo NANYANGWE
ZAMRA
16. Mr Amon SIAME
CIDRZ
17. Mr David DJOK
CIDRZ
18. Dr James NONDE
NTH
19. Dr Nfwama KAWATU
UTH-CH
20. Dr Emmanuel LICHE
UTH-Adult
21. Mr Davies Kunda SONDASHI
ADH
22. Mr Mwaba MULENGA
CHAI
23. Prof Mulindi MWANAHAMUNTHU
UTH-WNH
24. Dr Paul MULENGA
UTH-WNH
25. Dr Brown KAMANGA
UTH-Adult
26. Dr Angel PHIRI
UTH-WNH
27. Dr Selia NYANGO
UTH-WNH

INTRODUCTION

The criteria for the selection of essential medicines:

- The choice of essential medicines depends on factors which include: the pattern of prevalent diseases; the treatment facilities; the training and experience of available personnel; the financial resources; and the results of efficacy and safety evaluations obtained in controlled clinical trials and epidemiological studies and the performance in general use in a variety of healthcare settings.
- When several medicines are available for the same indication, only the medicine and the pharmacological form that provides the more convenient, benefit/risk ratio must be selected.
- When two or more medicines are therapeutically equivalent, the selection should be based on careful evaluation of their relative efficacy, safety, quality, price and availability. That is;
 - A medicine with which the health workers are familiar
 - A medicine with the most favourable pharmacokinetic properties
 - One that has been thoroughly investigated
 - In cost comparison, it must be medicine with the lowest cost of the total treatment, not only the unit cost of the medicine
 - And readily available medicine.

Most essential medicines must be formulated as single compounds. A fixed-dose combination should be accepted only if clinical documentation justifies the concomitant use of more than one medicine, and the combination provides a proven advantage over single compounds when administered separately in terms of therapeutic effect, safety, cost or patients adherence to treatment.

ZAMBIA ESSENTIAL MEDICINES LIST

	Medicine	Presentation	Level	VEN
1	Medicines used in anaesthesia			
1.1	General anaesthesia			
1.1.1	Intravenous and intramuscular anaesthetics			
1.1.1.1	Propofol	Emulsion for injection 10mg/ml	II - IV	V
1.1.1.2	Ketamine	Solution for injection 10mg/ml	II - IV	V
1.1.1.3	Etomidate	Powder for injection 1g and 500mg vials	II - IV	V
1.1.1.4	Thiopental sodium	Powder for injection 500mg vials	II - IV	
1.1.2	Volatile inhalation anaesthetics			
1.1.2.1	Sevoflurane	Inhalation liquid 250ml	II - IV	V
1.1.2.2	Isoflurane	Inhalation liquid 250ml	II - IV	V
1.1.2.3	Halothane	Inhalation liquid 250ml	II - IV	V
1.1.2.4	Nitrous oxide	Inhalation gas	II - IV	V
1.1.3	Muscle relaxant			
1.1.3.1	Suxamethonium	Injection 50mg/10ml	II- IV	V
1.1.3.2	Atracurium	Injection 10mg/ml	II- IV	V
1.1.3.3	Cisatracurium	Injection 2mg/ml or 5mg/ml (5ml/10ml); Lyophilized powder for reconstitution 20mg or 50mg	II- IV	E
1.1.3.4	Rocuronium	Injection 10mg/ml or 50mg/5ml (5ml or 10ml); Lyophilized powder for reconstitution: 50mg or 100mg	II- IV	V
1.2	Local anaesthetics			
1.2.1	Lignocaine	Solution for injection 2% w/v, 20mls	I - IV	V
1.2.2	Lignocaine with Adrenaline dental	Solution for injection	I - IV	E
1.2.3	Bupivacaine without preservatives	Solution for injection 50mg/ml, (2ml)	I - IV	V
1.2.4	Bupivacaine	Solution for injection 0.5% w/v	I - IV	E
1.2.5	Bupivacaine with glucose	Solution for injection 0.5% + 8% w/v	I - IV	V
1.3	Anticholinesterases			
1.3.1	Neostigmine	Solution for injection 2.5mg/ml, (1ml)	II - IV	V
2	Medicines acting on Gastrointestinal System			
2.1	Antacids			
2.1.1	Aluminium hydroxide + Magnesium trisilicate	Gel, Chewable tablets	I - IV	E

	Medicine	Presentation	Level	VEN
2.1.2	Aluminium hydroxide	Gel 4%; Tablets 500mg, Oral suspension 4%	I - IV	E
2.1.3	Magnesium trisilicate	Chewable tablets 250mg	I - IV	E
2.2	Antispasmodics			
2.2.1	Hyoscine butyl bromide	Solution for injection 20mg/ml (1ml), Tablets 10mg	I-IV	E
2.3	Anti-ulcer medicines			
2.3.1	Cimetidine	Tablets 200mg, 400mg, 800mg; Syrup/suspension 200mg/5ml, Solution for injection 100mg/ml	II - IV	N
2.3.2	Ranitidine	Tablets 150mg, 300mg, Solution for injection 25mg/ml	III - IV	E
2.3.3	Omeprazole	Capsule 10/20mg	I- IV	V
2.3.4	Esomeprazole	Tablet/capsule 20mg/40mg, Solution for injection 20mg	II- IV	E
2.4	Antidiarrhoeals			
2.4.1	Codeine phosphate	Tablets 15mg, 30mg, 60mg	III - IV	E
2.4.2	Loperamide	Tablets/Capsules 2mg, Syrup 1mg/ml	II - IV	E
2.5	Laxatives			
2.5.1	Lactulose	Suspension 66.7% w/v	I- IV	E
2.5.2	Glycerol	Suppository 1g, 4g	I - IV	E
2.5.3	Senna	Tablets 7.5mg, Suppositories	I - III	E
2.5.4	Bisacodyl	Tablets 5mg	II - IV	E
2.6	Medicines used for treating haemorrhoids			
2.6.1	Bismuth subgallate + Zinc oxide + Lidocaine hydrochloride	Suppository, Cream	II - IV	E
3	Medicines acting on the Central Nervous System			
3.1	Anxiolytics			
3.1.1	Clonazepam	Tablet 0.5mg	II-IV	E
3.1.2	Lorazepam	Tablets 2mg	III - IV	E
3.1.3	Midazolam	Solution for injection 5mg, 15mg	II-IV	E
3.1.4	Diazepam	Tablets 2mg, Solution for injection 5mg/ml (2ml)	I - IV	V
3.1.5	Chlordiazepoxide	Tablets/capsule 5mg, 10mg, and 25mg; solution for Injection 100mg/2mL ampoules	IV	E

	Medicine	Presentation	Level	VEN
3.2	Antipsychotics			
3.2.1	Chlorpromazine	Tablet 100mg tablet, Solution for injection 25mg/ml	I - IV	V
3.2.2	Haloperidol	Tablet 5mg, solution for injection 5mg/2ml,	I - IV	V
3.2.3	Fluphenazine	Solution for injection 25mg/ml	I-IV	V
3.2.4	Risperidone	Solution for injection 25mg/2mL	IV	E
3.2.5	Risperidone	Tablet 1mg/2mg	I – IV	V
3.2.6	Quetiapine	Tablet 25mg/50mg/100mg	I – IV	E
3.2.7	Olanzapine	Tablet 5mg/10mg	III - IV	E
3.2.8	Clozapine	Tablet 25mg/50mg	III – IV	E
3.2.9	Disulfiram	Tablet 25mg/50mg	IV	E
3.3	Selective serotonin reuptake inhibitors			
3.3.1	Fluoxetine	Tablets 20mg, 50mg	1- III	V
3.3.2	Sertraline	Tablet 60mg	III- IV	E
3.3.3	Citalopram	Tablet 10mg, 20mg	IV	E
3.3.4	Escitalopram	Tablet 10mg/20mg	IV	E
3.3.5	Mirtazapine	Tablet 5mg	IV	E
3.4	Tricyclic Antidepressants			
3.4.1	Amitriptyline	Tablets 25mg	II - IV	V
3.4.2	Imipramine	Tablets 25mg	II - IV	V
3.4.3	Clomipramine	Tablets 25mg	III – IV	E
3.5	Mood stabilizers			
3.5.1	Lithium carbonate	Tablets 300mg	IV	E
3.5.2	Sodium valproate	Tablets 200mg	I – IV	V
3.5.3	Divalproex sodium	Tablet 500mg	II – IV	V
3.6	Antiepileptic medicines			
3.6.1	Carbamazepine	Tablets 200mg, injection 5mg/ml	I – IV	V
3.6.2	Lamotrigine	Tablets 25mg, 50mg	I - IV	V
3.6.3	Ethosuximide	Capsules 250mg	IV	E
3.6.4	Phenobarbitone	Tablets 30mg, Solution for injection 200mg/ml	I – IV	V

	Medicine	Presentation	Level	VEN
3.6.5	Phenytoin	Tablets 100mg, Solution for injection 250mg	II - IV	E
3.6.6	Sodium valproate	Tablets 200mg, Syrup 200mg/5ml	I – IV	V
3.6.7	Gabapentin	Tablets 600mg, Oral solution 250mg/5ml	II – IV	E
3.6.8	Levetiracetam	Tablets 250mg, suspension 100mg/ml, injection 5mg/ml	II – IV	E

	Medicine	Presentation	Level	VEN
3.7	Medicines used in Parkinsonism and related disorders			
3.7.1	Bezhexol	Tablets 5mg	II – IV	V
3.7.2	Bromocriptine	Tablets 2.5mg	III - IV	E
3.7.3	Procyclidine	Tablets 5mg, injection 5mg/ml, (2ml)	II - IV	E
3.8	Medicines used for Nausea and Vomiting			
3.8.1	Cyclizine	Tablets 50mg, Solution for injection 50mg/ml	IV	E
3.8.2	Domperidone	Tablets 10mg	II - IV	E
3.8.3	Metoclopramide	Tablets 10mg, Solution for injection 5mg/ml (2ml)	I – IV	V
3.8.4	Prochlorperazine	Tablets 5mg	III - IV	E
3.8.5	Promethazine	Tablet 25mg, Solution for injection 25mg/ml (2ml)	I - IV	V
3.8.6	Ondansetron	Tablets 4mg, Oral suspension 2mg, Solution for injection 8mg/2ml	II - IV	V
3.9	Analgesics			
3.9.1	Non-opioids analgesics			
3.9.1.1	Paracetamol (Acetaminophen)	Tablets 100mg, 500mg, Suppository 125mg, 250mg, Syrup 120mg/5ml,	I - IV	V
3.9.1.2	Paracetamol (Acetaminophen)	Solution for injection 10mg/ml	II - IV	V
3.9.2	Non-Steroidal Anti-Inflammatory Medicines			
3.9.2.1	Aspirin	Tablets 75mg, 300mg	I – IV	V
3.9.2.2	Ibuprofen	Tablets 200mg, 400mg	I – IV	V

	Medicine	Presentation	Level	VEN	AWaRe
3.9.2.3	Diclofenac	Tablets 50mg, 100mg, Solution for injection 75mg, spray	I – IV	V	
3.9.2.4	Mefenamic acid	Tablets 250mg, 500mg, Suppository 125mg	II - IV	E	
3.9.3	Opioid analgesics				
3.9.3.1	Morphine	Powder 5g, Solution for injection 10mg/ml ampoule	II - IV	V	
3.9.3.2	Pethidine	Tablets 50mg, Solution for injection 50mg/ml	II - IV	E	
3.9.3.3	Tramadol	Tablets/Capsule 50mg; Solution for injection 50mg/ml	II - IV	E	
3.9.3.4	Fentanyl	Solution for injection 50mcg/ml/Patches 12mcg/50mcg Patches	III – IV	E	
3.9.4	Anti-migraine medicines				
3.9.4.1	Ergotamine tartrate	Tablets 1mg	II - IV	E	
4	Medicines used in the treatment of infections				
4.1	Antibacterial medicines				
4.1.1	Penicillins				
4.1.1.1	Benzathine penicillin	Powder for injection 2.4 MU vial	I - IV	V	A
4.1.1.2	Benzylpenicillin	Powder for injection 5 MU vial	I - IV	V	A
4.1.1.3	Phenoxymethylpenicillin	Tablets 250mg, Oral suspension 125mg/5ml	I - IV	V	A
4.1.2	Broad-spectrum penicillins				
4.1.2.1	Amoxycillin	Tablets/Capsules 250mg, Syrup 125mg/5ml	I - IV	V	A
4.1.2.2	Ampicillin	Powder for injection 500mg vial	II – IV	V	A
4.1.3	Penicillinase-resistant penicillins				
4.1.3.1	Amoxicillin + Clavulanic acid (Co-amoxiclav)	Tablets 375mg (250mg + 125mg), 625mg (500mg + 125mg)/Powder for injection 875/125mg	II – IV	V	A
4.1.3.2	Cloxacillin	Capsules 250mg, Powder for injection 500mg	I – IV	V	A
4.1.3.3	Flucloxacillin	Capsules 250mg, Powder for injection 250mg	III - IV	E	A

	Medicine	Presentation	Level	VEN	AWaRe
4.1.3.4	Piperacillin/Tazobactam	Injection, 2g/0.25g, 4g/0.5g vial	III-IV	V	W
4.1.3.5	Meropenem	Injection, 250mg,500mg,1g	III-IV	V	W
4.1.3.6	Vancomycin	Injection, 250mg,500mg,1g	III-IV	V	W
4.1.4	Aminoglycosides				
4.1.4.1	Gentamicin	Solution for injection 40mg/ml, (2ml)	I - IV	V	A
4.1.4.2	Amikacin	Injection 250mg, 500mg vial	III-IV	V	W
4.1.5	Sulphonamides				
4.1.5.1	Sulfamethoxazole + Trimethoprim (Co-trimoxazole)	Tablets 120mg, 480mg, Oral suspension 240mg/5ml, Solution for injection 480mg	I - IV	V	A
4.1.6	Quinolones				
4.1.6.1	Ciprofloxacin	Tablets 250mg, 500mg Solution for injection 2mg/ml 100ml,100ml bottle	I – IV	E	A
4.1.6.2	Nalidixic acid	Tablets 500mg, Oral suspension 300mg/5ml	I - IV	E	A
4.1.6.3	Ofloxacin	Tablets 400mg, Solution of injection 2mg/ml	II – IV	E	W
4.1.7	Nitro-furan medicines				
4.1.7.1	Nitrofurantoin	Tablets 50mg/100mg	I - IV	V	A
4.1.8	Macrolides				
4.1.8.1	Erythromycin	Tablets 250mg, Powder for injection 500mg vial, Oral suspension 125mg/5ml	I - IV	V	A
4.1.8.2	Azithromycin	Capsules/Tablets 250mg/500mg, Oral suspension 200mg/5ml	II - IV	V	A
4.1.8.3	Clarithromycin	Tablet 250mg, 500mg	II - IV	V	W
4.1.9	Lincosamides				
4.1.9.1	Clindamycin	Capsules 75mg, Oral suspension 75mg/5ml, Solution for injection 150mg/ml	III - IV	V	W
4.1.9.2	Clindamycin cream	Clindamycin Cream 15g- 30g	II – IV	V	A
4.1.10	Cephalosporins and Cephamycins				
4.1.10.1	Cefotaxime	Powder for injection 250mg, 500mg, 1g vial	II – IV	E	
4.1.10.2	Cefoxitine	Powder for injection 1g, 2g vial	II - IV	E	W

	Medicine	Presentation	Level	VEN	AWaRe
4.1.10.3	Ceftriaxone	Powder for injection 250mg, 500mg, 1g vial	I - IV	V	W
4.1.10.4	Cephalexin	Tablets/ Capsules 250mg, Oral suspension 125mg/5ml	I - IV	V	A
4.1.10.5	Cefuroxime	Tablets 250mg,500mg, Oral suspension 125m/5ml	II – IV	E	A
4.1.10.6	Cefepime	Powder for injection 1g, 2g vial	III - IV	E	W
4.1.10.7	Cefixime	Suspension, 100mg/5ml Tablet, 200mg, 400mg	III - IV	E	W
4.1.10.8	Cefpodoxime	Suspension 50mg/5ml Tablet, 100mg, 200mg	II-IV	E	W
4.1.11	Tetracyclines				
4.1.11.1	Doxycycline	Tablets/Capsule 100mg	I - IV	V	A
4.1.11.2	Tetracycline	Eye ointment 3%	I - IV	E	A
4.1.12	Nitroimidazoles				
4.1.12.1	Metronidazole	Tablets 200mg, Solution for infusion 5mg/ ml 100mls, Oral suspension 100mg/5ml, 100ml bottle	I - IV	V	A
4.1.12.2	Tinidazole	Tablets 500mg	I - IV	E	A
4.1.13	Other antibacterials				
4.1.13.1	Chloramphenicol	Capsules 250mg, Oral suspension 125mg/5ml, Powder for injection 1g vial	III – IV	E	A
4.2	Anti-tuberculosis medicines				
4.2.1	Rifampicin + Isoniazid	Tablets 150mg + 75mg	I - IV	V	A
4.2.2	Rifampicin + Isoniazid	Tablets 75mg + 50mg	I - IV	V	A
4.2.3	Rifampicin + Isoniazid + Ethambutol	Tablets 150mg + 75mg + 275mg	I - IV	V	A
4.2.4	Rifampicin + Isoniazid + Pyrazinamide	Tablets 75mg + 50mg + 150mg	I - IV	V	A
4.2.5	Rifampicin + Isoniazid + Ethambutol + Pyrazinamide	Tablets 150mg + 75mg + 275mg+ 400mg	I - IV	V	A
4.2.6	Ethambutol	Tablets 400mg	I - IV	V	A
4.2.7	Pyrazinamide	Tablets 400mg	I - IV	V	A
4.2.8	Isoniazid	Tablets 100mg,150mg	I - IV	V	A
4.2.9	Capreomycin	Powder for injection 1g	II - IV	V	R

	Medicine	Presentation	Level	VEN	AWaRe
4.2.10	Levofloxacin	Tablets 250mg	II - IV	V	W
4.2.11	Ethionamide	Tablets 250mg	II - IV	V	R
4.2.12	Cycloserine	Tablets 250mg	II - IV	V	R
4.2.13	Bedaquiline	Tablet 100mg	II - IV	V	R
4.2.14	Delamanide	Tablet 50mg	II - IV	V	R
4.2.15	Linezolid	Tablet 600mg	II - IV	V	R
4.2.16	Clofazimine	Tablet 100mg	II - IV	V	W
4.2.17	Moxifloxacin	Tablet 400mg	II - IV	V	W

	Medicine	Presentation	Level	VEN
4.3	Anti-leprosy medicines			
4.3.1	Clofazimine	Capsules 50mg,100mg	I - IV	V
4.3.2	Dapsone	Tablets 50mg, 100mg	I - IV	V
4.3.3	Rifampicin	Capsules 150mg, 300mg, Oral syrup 100mg/5ml	I - IV	V
4.4	Antifungal medicines (also see section 12.3 and 13.3)			
4.4.1	Amphotericin B	Solution for injection 50mg	II – IV	V
4.4.2	Clotrimazole	Topical cream 1%, Vaginal tablet 500mg, Mouth paint	I - IV	V
4.4.3	Fluconazole	Capsule 50mg, 150mg, 200mg, Solution for injection 2mg/ml	I - IV	V
4.4.4	Flucytosine	Tablet 250mg, Solution for injection 10mg/ml	II – IV	V
4.4.5	Griseofulvin	Tablets 125mg, 250mg, 500mg, Oral suspension 125mg/5ml	II – IV	E
4.4.6	Miconazole	Topical cream 2%	I - IV	E
4.4.7	Terbinafine	Tablet 250mg, Topical cream/ointment 1%	II - IV	E
4.4.8	Itraconazole	Tablets 100mg	II – IV	E
4.4.9	Nystatin	Vaginal tablets 100,000 IU, Oral suspension 100,000 IU, Tablets/Capsules 100,000 IU	I - IV	V
4.5	Anti-protozoal medicines			
4.5.1	Antimalarials			
4.5.1.1	Artemether + Lumefantrine	Tablets 20mg/120mg, 80/480mg	I - IV	V
4.5.1.2	Pyrimethamine + Sulphadoxine	Tablets 25mg/500mg	I - IV	V
4.5.1.3	Primaquine	Tablets 26.3mg	I - IV	V

	Medicine	Presentation	Level	VEN
4.5.1.4	Pyrimethamine	Tablets 25mg	I - IV	V
4.5.1.5	Dapsone	Tablets 25mg, 100mg	I - IV	V
4.5.1.6	Quinine	Tablets 300mg, Solution for injection 300mg/1ml (2ml)	I - IV	V
4.5.1.7	Artesunate	Powder for injection 60mg, 120mg, Rectal capsule 100mg	I - IV	V
4.5.1.8	Hydroxychloroquine	Suppository 100mg, 200mg Tablet 50mg tablet 200mg- 400mg	III - IV	V
4.5.2	Amoebocides (See section 4.1.11)			
4.6	Trypanomicides			
4.6.1	Melarsoprol	Solution for injection 3.6%	III - IV	V
4.6.2	Suramin sodium	Powder for injection 1g vial	III - IV	V
4.6.3	Pentamidine isethionate	Powder for nebulizer solution 300mg	III - IV	V
4.7	Antivirals			
4.7.1	Acyclovir	Tablets 200mg, 400mg, Topical cream 5%, Solution for injection 50mg/ml, Powder for injection 500mg, 1g vial, Ophthalmic ointment 3%	I - IV	V
4.7.2	Nirmatrelvir/ Ritonavir	Tablets 150mg/ 100mg	I - IV	E
4.7.3	Remdesivir	Injection 100mg	I - IV	E
4.8	Antiretroviral Medicines used in HIV infection			
4.8.1	Abacavir	Tablets 300mg	I- IV	V
4.8.2	Lamivudine	Tablets 150mg	I - IV	V
4.8.3	Zidovudine + Lamivudine	Tablets 60mg /30mg, 300mg/ 150mg	I- IV	V
4.8.4	Abacavir + Lamivudine	Tablets 60mg + 30mg; 120mg + 60mg	I - IV	V
4.8.5	Abacavir + Lamivudine+ Dolutegravir	60mg+30mg+5mg	I - IV	V
4.8.6	Tenofovir/Lamivudine/Dolutegravir	Tablets 300mg /300mg/50mg	I- IV	V
4.8.7	Tenofovir alafenamide/Emitricitabine/ Dolutegravir	Tablets 25mg/200/50mg	I - IV	V
4.8.8	Tenofovir/Emitricitabine	Tablets 300/200mg	I - IV	V
4.8.9	Nevirapine	Oral suspension 10mg/ml	I- IV	V
4.8.10	Etravirine	Tablets 100mg	IV	V
4.8.11	Ritonavir	Tablets 100mg	I - IV	V
4.8.12	Lopinavir/Ritonavir	Oral solution 80mg/20mg; Tablet 200mg/50mg, 100mg/25mg	I - IV	V
4.8.13	Lenacapavir	463.5 mg/1.5ml; 927mg/1.5ml solution for injection	IV	V
4.8.14	Cabotegravir	Injection 600mg/3mL	II - IV	V

	Medicine	Presentation	Level	VEN
4.9	Antihelminthics			
4.9.1	Mebendazole	Chewable tablets 100mg, 500mg	I - IV	V
4.9.2	Pyrantel pamoate	Tablets 125mg, Oral suspension 250mg/5ml	I - IV	E
4.9.3	Albendazole	Tablets 400mg	I - IV	V
4.10	Schistosomicides			
4.10.1	Praziquantel	Tablets 600mg	I - IV	V
4.11	Anti-filarials			
4.11.1	Diethylcarbamazine	Tablets 50mg	I - IV	E
4.11.2	Ivermectin	Tablets 3mg	III - IV	E
5	Medicines used for endocrine system disorders, obstetrics, gynecology and contraception			
5.1	Medicines used in Diabetes mellitus			
5.1.1	Insulins			
5.1.1.1	Rapid acting insulin (aspart, lispro)	Solution for injection 100IU/ml 10ml	II - IV	V
5.1.1.2	Short acting (soluble) Insulin	Solution for injection 100 IU/ml 10ml vial	I - IV	V
5.1.1.3	Insulin (Intermediate acting)	Solution for injection 100IU/ml 10ml	I - IV	V
5.1.1.4	Premixed/Biphasic- Regular and Intermediate (30/70)	Solution for injection 100IU/ml 10ml, Pre-filled penset 300IU/3ml	II- IV	V
5.1.1.5	Long-acting Insulin (Glargin, Determir)	Solution for injection 100IU/ml 10ml	I - IV	V
5.1.2	Glucagon-Like Peptide-1 Receptor Agonist			
5.1.2.1	Semaglutide	subcutaneous injections 0.25mg, 0.5mg, 1mg, 2mg	III - IV	V
5.1.3	Oral Antihyperglycaemics			
5.1.3.1	Sulphonylureas			
5.1.3.1.1	Glibenclamide	Tablets 5mg	I - IV	V
5.1.3.1.2	Gliclazide	Tablet 30mg	I - IV	E
5.1.3.1.3	Glimepiride	Tablets 1mg, 2mg	I - IV	V
5.1.3.1.4	Glimepirde + Metformin	Tablets 2mg + 500mg	I - IV	E
5.1.3.2	Biguanide			
5.1.3.2.1	Metformin	Tablets 500mg	I - IV	V
5.1.3.3	Dipeptidyl Peptidase-4 (DPP-4) Inhibitors			

	Medicine	Presentation	Level	VEN
5.1.3.3.1	Sitagliptin	Tablets 25mg, 50mg, 100mg	II - IV	E
5.1.3.3.2	Vildagliptin	Tablet 50mg, 100mg	II - IV	V
5.1.3.4	Sodium-Glucose co-transporter 2 (SGLT2) Inhibitors			
5.1.3.4.1	Dapagliflozin	Tablets 5mg, 10mg	III - IV	V
5.1.3.5	Thiazolidinediones			
5.1.3.5.1	Pioglitazone	Tablet 15mg, 30mg, 45mg	III - IV	E
5.2	Medicines for hypoglycaemia			
5.2.1	Glucagon	Powder & Solvent for injection 1mg	I - IV	V
5.3	Medicines acting on the thyroid			
5.3.1	Carbimazole	Tablets 5mg	II-IV	V
5.3.2	Iodine aqueous	Oral solution	III - IV	E
5.3.3	Thyroxine	Tablets 50mcg, 100mcg	II - IV	V
5.4	Corticosteroids			
5.4.1	Betamethasone	Injection 6mg/ml	I - IV	E
5.4.2	Dexamethasone	Tablets 500mcg, Solution for injection 4mg/ml (1ml or 2ml)	I - IV	V
5.4.3	Hydrocortisone sodium succinate	Powder for injection 100mg vial	I - IV	V
5.4.4	Prednisolone	Tablets 5mg	I - IV	V
5.4.5	Triamcinolone cream	Topical cream	I - IV	V
5.4.6	Triamimicinolone injection	40mg injection	II - V	V
5.5	Oestrogens and progestogens			
5.5.1	Norethisterone	Tablets 5mg	I - IV	V
5.5.2	Conjugated Oestrogens	Tablets 625mcg	III - IV	V
5.5.3	Micronized Progestogen	Tablets 200mcg	II – IV	E
5.5.4	Hormonal IUCD	Levonorgestrel 13.5-20mcg/day releasing device	I - IV	V
5.6	Androgens and anti-androgens			
5.6.1	Cyproterone	Tablets 50mg	III - IV	E
5.6.2	Stilboestrol	Tablets 1mg	III - IV	E
5.6.3	Testosterone undecanoate	Capsules 40mg, Solution for injection (oily depot) 250mg/ml, (1ml)	III - IV	E
5.7	Other endocrine medicines			

	Medicine	Presentation	Level	VEN
5.7.1	Bromocriptine	Tablets 2.5mg	III - IV	E
5.7.2	Clomiphene citrate	Tablets 50mg	II - IV	E
5.7.3	Danazol	Capsules 100mg	III - IV	E
5.7.4	Letrazole	Tablets 2.5mg	III - IV	E
5.8	Medicines used in obstetrics and gynaecology			
5.8.1	Medicines acting on smooth muscle			
5.8.1.1	Anticonvulsants			
5.8.1.1.1	Magnesium sulphate	Solution for injection 50%	I – IV	V
5.8.1.2	Prostaglandin Analogues and Oxytocics			
5.8.1.2.1	Dinoprostone	Tablets 500mcg, Solution for injection 1mg/ml	III - IV	E
5.8.1.2.2	Ergometrine maleate	Tablets 250mcg, 500mcg, Solution for injection 200mcg/ml	II - IV	V
5.8.1.2.3	Ergometrine + Oxytocin	Solution for injection 50mcg/5 IU	II - IV	E
5.8.1.2.4	Oxytocin	Solution for injection 10 IU/ml	I – IV	V
5.8.1.2.5	Carbetocin (heat stable)	Solution for injection 100mcg/ ml	I - IV	V
5.8.1.2.6	Misoprostol	Tablets 200mcg/25 mcg	I - IV	V
5.8.1.2.7	Mifepristone	Tablets 200mg/10mg/50mg	II - IV	V
5.8.1.2.8	Mifepristone + Misoprostol	Tablets 200mg/200mcg	II-IV	V
5.8.1.3	Myometrial relaxants			
5.8.1.3.1	Salbutamol	Solution for injection 500mcg/ml (1ml)	II - IV	V
5.8.1.3.2	Nifedipine	Immediate release capsule/tablet, 10mg	I - IV	V
5.8.1.4	Other medicines administered to the pregnant woman			
5.8.1.4.1	Dexamethasone phosphate	Solution for injection 4mg/ ml	I – IV	V
5.8.1.4.2	Tranexamic acid	Solution for injection 100mg/ ml Tablets 500mg	I – IV III - IV	V E
5.8.1.4.3	Etamsylate	Tablets 500mg, Solution for injection 100mg/ ml Tablets 500mg	I – IV III - IV	V E
5.9	Contraceptives			
5.9.1	Combined oral contraceptives			

	Medicine	Presentation	Level	VEN
5.9.1.1	Ethinylestradiol/levonorgestrel	Tablets 30mcg/150mcg	I - IV	V
5.9.2	Emergency contraception			
5.9.2.1	Levonorgestrel	Tablets 750mcg, 1.5mg	I - IV	V
5.9.3	Progesterone-only oral contraceptives			
5.9.3.1	Levonorgestrel	Tablets 30mcg	I - IV	V
5.9.4	Progesterone-only injectable contraceptives			
5.9.4.1	Medroxyprogesterone acetate	Suspension for injection 150mg/ml, 1ml Pre-filled subcutaneous injection 104mg/0.65ml	I - IV	V
5.9.4.2	Norethisterone enanthate	Solution/Emulsion for injection 200mg/ml, 1ml	I - IV	V
5.9.5	Barrier methods			
5.9.5.1	Female condoms	Artificial plastic sheath	I - IV	V
5.9.5.2	Male condoms	Latex sheath with/without spermicide	I - IV	V
5.9.5.3	Copper coil intrauterine device	Copper long coil type (Copper T 380A) Intrauterine device (IUD)	I - IV	V
5.9.5.4	Levonorgestrel-releasing intrauterine system	Intrauterine device LNG-IUS 52mg	I - IV	V
5.9.5.5	Menfegol spermicidal vaginal foaming	Forming tablets	I - IV	E
5.9.6	Implants			
5.9.6.1	Levonorgestrel implant	Two rods, 75 mg each	I – IV	V
5.9.6.2	Etonogestrel implant	Single rod- releasing implant 68 mg	I – IV	V
6	Medicines used in the treatment of respiratory system disorders and allergy			
6.1	Anti-asthmatic medicines and medicines for chronic obstructive pulmonary disorder			
6.1.1	Adrenaline	Solution for injection 1 in 1000, (1ml)	I - IV	V
6.1.2	Salbutamol	Tablets 2mg, Oral syrup 2mg/5ml Inhaler 100mcg/dose, Nebuliser liquid 2mg/ml	I - IV	V
6.2	Corticosteroids			
6.2.1	Hydrocortisone sodium succinate	Powder for injection 100mg vial	I - IV	V
6.2.2	Prednisolone	Tablets 5mg	I – IV	V

	Medicine	Presentation	Level	VEN
6.2.3	Mometasone cream	topical cream/ointment 0.1%	III -IV	V
6.3	Asthma prophylaxis therapy			
6.3.1	Beclomethasone	Inhaler 50mcg/dose	I – IV	V
6.3.2	Sodium cromoglicate	Inhaler 5mg/dose	II - IV	E
6.3.3	Ipratropium bromide	Inhaler 20mcg/ metered dose	II - IV	E
6.3.4	Budesonide + Formoterol	Inhaler 100mcg + 6mcg or 200mcg + 6mcg	II – IV	V
6.4	Antihistamines			
6.4.1	Chlorphenamine	Syrup, Tablets 4mg	I - IV	V
6.4.2	Promethazine	Syrup, Tablets 10mg, Solution for injection 5mg/ml	I - IV	E
6.4.3	Loratidine	Oral liquid 1mg/ml, Tablets 10mg	I - IV	E
6.4.4	Cetirizine	Oral liquid 1mg/ml, tablet 10mg	I - IV	V
6.5	Oxygen therapy			
6.5.1	Oxygen	Medical gas	I - IV	V
6.6	Apnea of Prematurity			
6.6.1	Caffeine Citrate	10mg/ml	II-IV	V
6.6.2	Surfactant (Beractant)	Injection 25mg/ml	II-IV	V
7	Medicines used in the treatment of cardiovascular system disorders			
7.1	Cardiac glycosides			
7.1.1	Digoxin	Tablets 250mcg, Solution for injection 250mcg/ml, (2ml), Elixir 50mcg/ml	II-IV	V
7.2	Diuretics			
7.2.1	Thiazides			
7.2.1.1	Bendrofluzide	Tablets 5mg	II - IV	E
7.2.1.2	Hydrochlorthiazide	Tablets 25mg, 50mg	I – IV	E
7.2.2	Loop diuretics			
7.2.2.1	Frusemide	Tablets 40mg, Solution for injection 10mg/ml	I – IV	V
7.2.3	Potassium-sparing diuretics			
7.2.3.1	Amiloride + Hydrochlorthiazide	Tablets 5mg/50mg	I – IV	V
7.2.4	Osmotic diuretics			
7.2.4.1	Mannitol	Solution for injection 20% (250ml bottle)	I – IV	V

	Medicine	Presentation	Level	VEN
7.3	Antiarrhythmic medicines			
7.3.1	Amiodarone	Tablets 100mg, Solution for injection	II – IV	E
7.3.2	Atenolol	Tablets 50mg	I – IV	V
7.3.3	Digoxin	Tablets 250mcg, Solution for injection 250mcg/ml (2ml)	II - IV	V
7.3.4	Lignocaine cardiac	Solution for injection 1%, (10ml, 25ml)	II – IV	V
7.3.5	Quinidine	Tablets 200mg, 300mg	III – IV	V
7.4	Anti-angina medicines			
7.4.1	Atenolol	Tablets 50mg	I – IV	V
7.4.2	Glyceryl trinitrate	Sub-lingual tablets 500mcg	II-IV	V
7.4.3	Isosorbide mononitrate	Tablets 10mg	II - IV	E
7.4.4	Nifedipine	Tablets or Capsules 10mg, 20mg	I – IV	E
7.5	Antihypertensive medicines			
7.5.1	Thiazide diuretics			
7.5.1.1	Hydrochlorthiazide	Tablets 50mg, 25mg	I - IV	V
7.5.2	Potassium-sparing diuretics			
7.5.2.1	Amiloride + Hydrochlorthiazide	Tablets 5mg/50mg	I – IV	V
7.5.2.2	Spironolactone	Tablets 25mg	I – IV	V
7.5.2.3	Eplerenone	Tablet 25mg, 50mg	II-IV	E
7.5.3	Beta- adrenoceptor blockers			
7.5.3.1	Atenolol	Tablets 50mg	I – IV	E
7.5.3.2	Propranolol	Tablets 10mg, 40mg	I – IV	E
7.5.3.3	Carvedilol	Tablets 3.125mg, 6.25mg, 12.5mg	I – IV	V
7.5.3.4	Labetalol	Tablets 100mg/50mg, Solution for injection 5mg/ml	II – IV	V
7.5.3.5	Metoprolol	Tablets 50mg, 100mg	II – IV	E
7.5.4	Vasodilators			
7.5.4.1	Hydralazine	Tablets 25mg, Solution for injection 20mg ampoule	I – IV	V
7.5.5	Angiotensin converting enzyme (ACE) inhibitors			
7.5.5.1	Captopril	Tablets 25mg	II – IV	E
7.5.5.2	Lisinopril	Tablets 5mg, 10mg, 25mg	II – IV	E

	Medicine	Presentation	Level	VEN
7.5.5.3	Enalapril	Tablets 5mg, 10mg, 20mg	I – IV	V
7.5.6	Angiotensin II receptor blockers			
7.5.6.1	Losartan	Tablets 25mg, 50mg	I – IV	V
7.5.6.2	Losartan + Hydrochlorthiazide	Tablets 50mg/12.5mg	I - IV	E
7.5.6.3	Telmisartan + Hydrochlorthiazide	Tablets 40mg/12.5mg	I - IV	V
7.5.6.4	Sacubitril + Valsartan	Tablet 24mg/26mg, 49mg/51mg	II-IV	E
7.5.7	Calcium channel blockers			
7.5.7.1	Nifedipine	Tablets or Capsules 10mg, 20mg	I – IV	V
7.5.7.2	Verapamil	Tablets 40mg	III - IV	E
7.5.7.3	Amlodipine	Tablets 5mg, 10mg	I – IV	V
7.5.8	Centrally acting antihypertensives			
7.5.8.1	Methyldopa	Tablets 250mg, 500mg	I - IV	V
7.6	Medicines used in shock - sympathomimetics			
7.6.1	Adrenaline	Solution for injection 1 in 1000 (1mg/ml)	I - IV	V
7.7	Alpha-adrenoceptor blocking agents			
7.7.1	Prazosin	Tablets 500mcg, 1mg	III - IV	E
7.8	Lipid-regulating medicines			
7.8.1	Statins			
7.8.1.1	Simvastatin	Tablets 20mg, 40mg	II – IV	E
7.8.1.2	Atorvastatin	Tablets 20mg, 40mg	II - IV	V
7.9	Inotropic medicines			
7.9.1	Dopamine	Solution for injection 40mg/ml	II – IV	E
7.9.2	Dobutamine	Solution for injection 100mg	II - IV	V
8	Medicines used in the treatment of malignant diseases: Anti-neoplastic medicines			
8.1	Actinomycin D (Dactinomycin)	Powder for injection 500mcg	III - IV	V
8.2	Asparaginase	Powder for injection 1000 IU	III - IV	V
8.3	Azathioprine	Tablets 50mg, injection 50mg vial	III - IV	V
8.4	Bleomycin	Powder for injection 15 000-unit ampoule	III – IV	V
8.5	Busulphan	Tablets 500mcg	IV	V
8.6	Calcium folinate	Tablets 15mg	IV	V

	Medicine	Presentation	Level	VEN
8.7	Carboplatin	Solution for injection 10mg/ml	IV	V
8.8	Carmustine	Powder for injection 100mg vial	IV	V
8.9	Chlorambucil	Tablets 2mg	IV	V
8.10	Cisplatin	Solution for injection 1mg/ml	IV	V
8.11	Cyclophosphamide	Tablets 50mg, Powder for injection 100mg	III - IV	V
8.12	Irinotecan	Solution for injection 20mg/ml	III - IV	V
8.13	Cytarabine (Cytosine arabinoside)	Powder for injection 100mg, 500mg, 1g vial	IV	V
8.14	Cyproteron acetate	Tablets 50mg, 100mg	IV	V
8.15	Dacarbazine	Powder for injection 200mg vial	IV	V
8.16	Daunorubicin	Powder for injection 20mg vial	IV	V
8.17	Doxorubicin	Powder for injection 10mg, 50mg	III – IV	V
8.18	Liposomal Doxorubin	20mg/ml	III - IV	E
8.19	Etoposide	Solution for IV infusion 20mg/ml	IV	V
8.20	Fludarabine	Tablets 10mg, Solution for injection, infusion 40mg/m ²	IV	V
8.21	Filgrastim	Solution for injection 300mcg/ml	IV	V
8.22	Fluorouracil	Solution for injection 25mg/ml	III – IV	V
8.23	Hydroxyurea	Capsules 500mg	I – IV	V
8.24	Ifosfamide	Powder for injection 1g, 2g vial	IV	V
8.25	Imatinib	Tablets 100mg	IV	V
8.26	Interferon	Solution for injection 300mg	IV	V
8.27	Lomustine	Capsules 40mg	IV	V
8.28	Melphalan	Tablets 2mg, Solution for injection 100mg	IV	V
8.29	Mercaptopurine	Tablets 50mg	IV	V
8.30	Methotrexate	Tablets 2.5mg, Solution for injection 50mg	II – IV	V
8.31	Mitomycin	Solution for injection 40mg	IV	V
8.32	Mustine	Solution for injection 10mg	IV	V
8.33	Paclitaxel	Solution for IV infusion 6mg/ml	IV	V
8.34	Procarbazine	Capsules 50mg	IV	V
8.35	Stilboestrol (Diethylstilbestrol)	Tablets 1mg	IV	V
8.36	Tamoxifen	Tablets 20mg	III – IV	V

	Medicine	Presentation	Level	VEN
8.37	5% Fluorouracil Cream	Topical Cream 15g - 30g	III - IV	V
8.38	Sun screen protector	Topical lotion with SPF 30, 40, 50	I - IV	V
8.39	Tacrolimus	Tablet 1mg	II - IV	V
8.40	Thioguanine	Tablets 40mg	IV	V
8.41	Vinblastine	Solution for injection 1mg/ml	III – IV	V
8.42	Vincristine	Solution for injection 1mg, 5mg	III – IV	V
8.43	Letrozole	Tablets 2.5mg	III - IV	V
8.44	Anastrozole	Tablet 1mg; oral solution 1mg/ml	III - V	V
9	Medicines acting on the eye			
9.1	Ophthalmic diagnosis			
9.1.1	Fluorescein sodium	Eye drops, strips	III - IV	E
9.2	Anti-infective preparations			
9.2.1	Antibacterial			
9.2.1.1	Chloramphenicol	Eye drops 0.5%, Eye ointment 1%	II - IV	E
9.2.1.2	Chloramphenicol + Dexamethasone	Eye drops 15%, 0.1%	III - IV	E
9.2.1.3	Tetracycline	Eye ointment 1%	I - IV	E
9.2.1.4	Oxy-tetracycline + Hydrocortisone	Eye drops 3%, 1%	III - IV	E
9.2.1.5	Neomycin + Betamethasone	Eye drops 0.5%, 0.1%	III - IV	E
9.2.1.6	Gentamicin	Eye drops 0.3%	II - IV	E
9.2.1.7	Ofloxacin	Solution 0.3%	III - IV	E
9.2.2	Antifungals (Preparations are not generally available and could be prepared extemporaneously)			
9.2.2.1	Povidone Iodine	Eye drops 0.5%	III - IV	E
9.2.2.2	Natamycin	Eye suspension 5%	IV	E
9.2.3	Antiviral			
9.2.3.1	Aciclovir	Eye ointment	III – IV	E
9.3	Anti-inflammatory preparations			
9.3.1	Hydrocortisone acetate	Eye drops, eye ointment	II - IV	E
9.3.2	Dexamethasone	Eye drops 0.1%	III – IV	E
9.3.3	Tropicamide	Eye drops 1%	III – IV	E
9.3.4	Sodium cromoglycate	Eye drops 2%	III - IV	E

	Medicine	Presentation	Level	VEN
9.4	Miotics and anti-glaucoma medicines			
9.4.1	Pilocarpine	Eye drops 2%, 4%	III – IV	E
9.5	Mydriatic medicines			
9.5.1	Atropine sulphate	Eye drops 1%	III - IV	E
9.6	Systemic preparations			
9.6.1	Acetazolamide sodium	Tablets 250mg	III - IV	V
9.7	Local anaesthetics			
9.7.1	Lignocaine hydrochloride	Eye drops 4%	III - IV	E
9.8	Prostaglandin Analogue			
9.8.1	Latanoprost	Eye drops 50mcg/ml	IV	E
9.9	Sympathomimetics			
9.9.1	Dipivefrine	Eye drops 0.1%	IV	E
9.10	Beta-adrenoceptor blocker			
9.10.1	Timolol maleate	Eye drops 0.25%, 0.5%	III - IV	E
9.11	Diuretics			
9.11.1	Cyclopenthiiazide	Tablets 0.5mg	IV	E
9.12	Artificial tears			
9.12.1	Hypromellose	Eye drops 0.3mg	III - IV	E
9.13	Hyperosmotic agents			
9.13.1	Mannitol	Solution in water 20%	II – IV	E
9.13.2	Urea	Solution 30% in 10% invert sugar	III - IV	E
10	Blood and Blood Products			
10.1	Anti-coagulants			
10.1.1	Heparin (Unfractionated)	Solution for injection 5000IU/ml, 1ml	II - IV	V
10.1.2	Enoxaparin	Solution for injection 40mg, 60mg and 80mg pre-filled syringe	I – IV	V
10.1.3	Warfarin	Tablets 10mg, 5mg	II - IV	V
10.1.4	Rivaroxaban	Tablet 2.5mg, 10mg	II – IV	V
10.1.5	Dabigatran	Tablet/capsule 75mg, 110mg, 150mg	II – IV	V
10.2	Anti-haemorrhagic medicines			
10.2.1	Aminocaproic acid	Effervescent powder 3g, Oral suspension 10mg/5ml	III - IV	E

	Medicine	Presentation	Level	VEN
10.2.2	Tranexamic acid	Solution for injection 100mg/ml, Tablets 500mg	I – IV	V
10.2.3	Fibrinogen	Dry or freeze-dried powder for injection	III - IV	V
10.2.4	Human anti-haemophiliac fraction (dried)	Solution for reconstitution 3 units/ml	IV	E
10.2.5	Phytomenadione (Vitamin K)	Solution for injection 10mg/ml, (1ml)	I – IV	V
10.3	Haematinics			
10.3.1	Ferrous sulphate	Tablets 50mg, 200mg	I - IV	V
10.3.2	Folic acid	Tablets 5mg, 400mcg	I - IV	V
10.3.3	Hydroxocobalamin (Vitamin B12)	Solution for injection 1mg/ml, 1ml	I – IV	V
10.3.4	Iron Sucrose	Injection 20mg/ml (5ml ampoule)	II - IV	E
11	Nutrition			
11.1	Vitamins, minerals and dietary supplements			
11.1.1	Ascorbic acid (vitamin C)	Tablets 50mg, 200mg	I - IV	V
11.1.2	Calcium gluconate	Solution for injection 10%, (5ml, 10ml)	I – IV	V
11.1.3	Ergocalciferol (Vitamin D)	Tablets 50,000 IU, solution 3000 IU/ml	I – IV	E
11.1.4	Nicotinamide	Tablets 50mg, 100mg 200mg	II - IV	E
11.1.5	Pyridoxine (Vitamin B6)	Tablets 25mg, 50mg	I - IV	V
11.1.6	Retinol (Vitamin A)	Capsules/ Tablets 200,000IU	I - IV	V
11.1.7	Riboflavin (Vitamin B2)	Tablets 5mg	III - IV	E
11.1.8	Thiamine (Vitamin B1)	Tablets 50mg, Solution for injection 100mg/5ml	I – IV	V
11.2	Electrolyte and water replacement			
11.2.1	Orally administered			
11.2.1.1	Oral rehydration salts	Powder sachets 27.9g to make 1 litre	I - IV	V
11.2.1.2	Potassium chloride	Tablets slow-release 600mg	II – IV	E
11.2.2	Infusions			
11.2.2.1	Dextrose (glucose)	Solution 5%, 10, 20, 50%	I - IV	V
11.2.2.2	Potassium chloride	Solution 11.2%	II - IV	E
11.2.2.3	Sodium bicarbonate	Solution 4.2%	I – IV	V
11.2.2.4	Sodium chloride (normal saline)	Solution 0.9% ,3%	I - IV	V
11.2.2.5	Sodium lactate and glucose (Darrow's)	Solution, full and half strength	I - IV	V

	Medicine	Presentation	Level	VEN
11.2.2.6	Sodium lactate compound (Ringers lactate)	Solution	I - IV	V
11.2.2.7	Water for injection	Solution 2ml, 5ml, 10ml	I - IV	V
11.2.3	Plasma substitutes			
11.2.3.1	Dextran 40, 70	Solution for injection 10%, 6%	II - IV	V
11.2.3.2	Gelatin (as polygeline)	Solution for injection 3.5	III - IV	E
12	Medicines acting on the skin			
12.1	Topical corticosteroids			
12.1.1	Betamethasone	Cream/ Ointment 0.1%	I – IV	E
12.1.2	Hydrocortisone	Cream/ Ointment 1%	I - IV	V
12.1.3	Triamcinolone cream	Cream/ Ointment 1%	I - IV	V
12.2	Soothing preparations/ immunomodulating drug			
12.2.1	Calamine	Lotion	I - IV	E
12.2.2	Sun Screen Protection Factor SPF	SPF 30, 40, 50 Lotion 100ml, 200ml	I – IV	V
12.2.3	Aqueous Cream/lotion	Cream/lotion 150g, 250g 500g	I - IV	V
12.2.4	Imiquimod cream	Topical cream 5%	II – IV	E
12.2.5	Tacrolimus cream	Topical cream/ ointment 0.03%, 0.1%	III - IV	E
12.3	Topical antifungal preparations			
12.3.1	Miconazole nitrate	Cream 2%	I – IV	V
12.3.2	Ketoconazole	Cream	I - IV	E
12.4	Oral antifungals			
12.4.1	Griseofulvin	Tablets 250mg, 500mg	I – IV	E
12.4.2	Terbinafine	Tablets 250mg	II – IV	V
12.5	Topical anti-bacterial preparations			
12.5.1	Mupirocin	Cream, Ointment 2%	I - IV	E
12.5.2	Silver sulfadiazine	Cream 1%	I - IV	V
12.6	Antiseptic preparations			
12.6.1	Potassium permanganate	Topical solution 1:10,000	I - IV	E
12.7	Topical anti-parasitic preparations			
12.7.1	Benzyl benzoate	Lotion 25%	I - IV	E
12.7.2	Malathion	Lotion 0.5%	I - IV	E
12.7.3	Permethrin	Cream 1%	I - IV	V

	Medicine	Presentation	Level	VEN
12.8	Keratoplastics and keratolytics			
12.8.1	Coal tar	Solution 5%	I - IV	V
12.8.2	Dithranol	Ointment 1%	III - IV	V
12.8.3	Podophylline	Paint 15% in compound benzoin tincture	II – IV	V
12.8.4	Silver Nitrate Pencil	Pencil/Ointment	I - IV	E
12.8.5	Salicylic acid	Ointment 5%, 10%, 20%	I - IV	E
12.9	Acne preparations			
12.9.1	Salicylic acid	Lotion	I - IV	E
12.9.2	Benzyl peroxide	Lotion	I - IV	V
12.9.3	Tretinoin cream 0.1%	Cream /ointment	II - IV	V
12.9.4	Isotretinoin	10mg, 20mg Tablet/Capsule	III - IV	V
12.10	Surgical disinfectants			
12.10.1	Sodium hypochlorite	Solution 0.1% available chlorine	I - IV	V
12.10.2	Chloroxylenol	Concentrated solution 4.8%	I - IV	E
12.11	Antiseptics			
12.11.1	Cetrimide	Solution 1%	I - IV	E
12.11.2	Chlorhexidine gluconate	Concentrated solution 5%	I - IV	V
12.11.3	Chlorhexidine + Cetrimide	Concentrated solution (1.5%/ 15%)	I - IV	V
12.11.4	Povidone iodine	Solution 10%	I - IV	E
12.12	Topical antivirals			
12.12.1	Acyclovir	Cream 5%, Tablets 200mg	I – IV	E
13	Medicines used in the treatment of diseases of the ear, nose and throat			
13.1	Medicines acting on the ear			
13.1.1	Betamethasone	Ear drops	I – IV	E
13.1.2	Gentamicin + Hydrocortisone	Ear drops	II - IV	E
13.1.3	Sodium bicarbonate	Ear drops	III - IV	E
13.1.4	Olive oil (Vegetable oil)	Ear drops	I - IV	E
13.1.5	Acetic acid	Solution 2%	I - IV	E
13.2	Medicines acting on the nose: topical nasal decongestants			
13.2.1	Saline	Nasal drops	II - IV	E
13.2.2	Xylometazoline	Nasal drops 0.25%, 0.05%	I - IV	E

	Medicine	Presentation	Level	VEN
13.3	Medicines acting on the throat			
13.3.1	Chlorhexidine	Mouth wash 0.2%	I - IV	E
13.3.2	Miconazole	Oral gel	I - IV	E
13.3.3	Nystatin	Oral suspension	I - IV	E
14	Medicines used for the treatment of musculoskeletal disorders			
14.1	Medicines used for rheumatic diseases			
14.1.1	Acetyl salicylic acid	Tablets 300mg	I - IV	V
14.1.2	Ibuprofen	Suspension 100mg/5ml Injection 10mg/ml Tablets 200mg	I - IV	E
14.1.3	Hydroxychloroquine	Tablets 200mg	III - IV	V
14.2	Medicines used for gout			
14.2.1	Allopurinol	Tablets 100mg	II – IV	E
14.2.2	Colchicine	Tablets 500mcg	II – IV	E
15	Immunological products			
15.1	Antisera, immunoglobulins and antitoxins			
15.1.1	Anti-D immunoglobulin	Solution for Injection 100mcg (500IU), 300mcg (1500IU)	II - IV	V
15.1.2	Diphtheria antitoxin	Injection 20,000IU/vial	II - IV	V
15.1.3	Mamba anti-sera	Injection 10,000IU/vial	I - IV	V
15.1.4	Polyvalent snake anti-sera	Injection 10,000IU, 20,000IU per vial	I – IV	V
15.1.5	Tetanus antitoxin	Injection 250IU, 500IU, 1500IU, 3000IU per vial	I - IV	V
15.2	Vaccines			
15.2.1	Bacillus Calmette-Guerin (BCG)	Injection 1-8x10 ⁸ , CFU/vial	I - IV	V
15.2.2	Diphtheria-pertussis	Injection 0.5ml	I - IV	V
15.2.3	Tetanus	Injection 0.5ml	I - IV	V
15.2.4	Haemophilus influenza B	Injection 10mcg, 25mcg per 0.5ml	I - IV	V
15.2.5	Hepatitis B (Pentavalent)	Injection 10-25mcg per 0.5ml	I - IV	V
15.2.6	Measles + Rubella	Injection 10,000+1,000 (TCID) per 0.5ml	I - IV	V
15.2.7	Poliomyelitis	Injection 0.5ml dose	I - IV	V
15.2.8	Rabies	Injection 2.5IU/ml	I - IV	V

	Medicine	Presentation	Level	VEN
15.2.9	Tetanus toxoid (TT)	Injection 5-10 Units/0.5ml	I - IV	V
15.2.10	Typhoid	Injection 25mcg/0.5ml	I – IV	E
15.2.11	Yellow fever	Injection 10,000IU/0.5ml	II – IV	E
15.2.12	Human Papilloma Virus (HPV)	Injection 0.5ml	I – IV	V
15.2.13	Rota Virus	1.0-2.0 ml dose for oral administration	I – IV	V
15.2.14	Pneumococcal Conjugate Vaccine 13	Injection 0.5ml	III - IV	E
15.2.15	Cholera	Liquid for oral administration	I – IV	V
16	Antidotes and other substances used in poisoning			
16.1	General treatment of poisoning			
16.1.1	Activated charcoal	Powder	I - IV	V
16.1.2	Ipecacuanha	Syrup 0.14% ipecacuanha alkaloids	I - IV	V
16.2	Specific treatment of poisoning			
16.2.1	Atropine	Injection 1mg/ml (1ml)	I – IV	V
16.2.2	Naloxone	Injection 400mcg/ml	II – IV	V
16.2.3	Pralidoxime mesylate	Injection 200mg/ml, (5ml)	I – IV	V
16.2.4	Glycopyrronium bromide	Injection 500mcg/ml	III - IV	V
16.2.5	N-acetylcysteine	Solution 20%	II – IV	E
16.2.6	Protamine sulphate	Injection 10mg/ml	II – IV	V

APPENDICES

FORM FOR PROPOSING REVISIONS IN ZAMBIA ESSENTIAL MEDICINES LIST FORMULARY ADDITION/DELETION/ CHANGE OF PRESENTATION SPECIAL AUTHORISATION FORM

Section A To be completed by reporting facility) / proposer	Name of medication to be added / deleted / change of presentation or other (generic / brand): _____ Desired Dosage: (Tick) ___ Tablet ___ Capsule ___ Injection Other (specify) _____ Estimated usage: (Tick) ___ Routine ___ Emergency ___ Clinical Evaluation Is similar- acting medication stocked now in the pharmacy? ___ Yes ___ No Reason for addition / deletion /change of presentation or other If addition, please explain the advantage of this medication: _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ Name of proposer: _____ Signature: _____ Date: _____	Pertinent Pharmacological Data On Medication _____ Therapeutic Action and Indication for Use: _____ _____ _____ _____ Side effects, toxicity, and Precautions: Side effects: Relative contraindications: Caution: Dosages: (Maximum and Minimum) References: 1) 2)
--	--	---

SECTION B To be completed by Formulary Committee	FORMULARY COMMITTEE EVALUATION Cost of requested medication_____ Cost of similar –acting item stocked _____ Manufacturer/Registration status_____ Remarks (Advantages, Disadvantages): Chairman of Formulary Committee _____ Date_____	
SECTION C To be completed by the formulary committee	FORMULARY COMMITTEE REPORT Determination: ____Rejected ____Approved: Level of use: ____ (e.g. For specialists use) Reasons: Formulary committee chairperson _____ _____ Date _____	

NOTES

NOTES

